$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

$pbyi Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000156459021009840 Filed on March 01, 2021

Income Statement

Concept	2020 Q4	2020	2019 Q4
Revenue	$52.56M	$225.1M	$62.92M
YoY Change	-16.47%	-17.32%	-11.48%
Cost Of Revenue	$10.94M	$39.37M	$10.14M
YoY Change	7.89%	6.95%	-2.12%
Gross Profit	$41.62M	$185.7M	$52.78M
YoY Change	-21.14%	-21.11%	-13.08%
Gross Profit Margin	79.19%	82.51%	83.88%
Selling, General & Admin	$28.61M	$118.5M	$30.02M
YoY Change	-4.7%	-16.35%	-26.66%
% of Gross Profit	68.74%	63.79%	56.88%
Research & Development	$24.16M	$97.65M	$30.24M
YoY Change	-20.11%	-26.5%	-21.11%
% of Gross Profit	58.05%	52.57%	57.29%
Depreciation & Amortization	$2.940M	$900.0K	$1.900M
YoY Change	54.74%	0.0%	-9.52%
% of Gross Profit	7.06%	0.48%	3.6%
Operating Expenses	$52.76M	$255.5M	$60.27M
YoY Change	-12.46%	-17.94%	-23.96%
Operating Profit	-$11.14M	-$30.40M	-$7.490M
YoY Change	48.73%	-22.14%	-59.6%
Interest Expense	-$3.550M	$14.05M	-$2.580M
YoY Change	37.6%	-6.48%	-17.31%
% of Operating Profit
Other Income/Expense, Net	$70.00K	-$29.39M	$100.0K
YoY Change	-30.0%	-19.48%	-600.0%
Pretax Income	-$14.79M	-$59.79M	-$11.15M
YoY Change	32.65%	-20.85%	-63.66%
Income Tax	$210.0K	$207.0K	$50.00K
% Of Pretax Income
Net Earnings	-$14.99M	-$60.00M	-$11.20M
YoY Change	33.89%	-20.64%	-63.51%
Net Earnings / Revenue	-28.53%	-26.65%	-17.8%
Basic Earnings Per Share	-$0.38	-$60.00K
Diluted Earnings Per Share	-$0.38	-$1.515M	-$286.8K
COMMON SHARES
Basic Shares Outstanding	39.88M	39.58M
Diluted Shares Outstanding	39.88M	39.58M

Balance Sheet

Concept	2020 Q4	2020	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$93.40M	$93.40M	$111.6M
YoY Change	-16.31%	-16.31%	-32.53%
Cash & Equivalents	$85.29M	$85.30M	$60.04M
Short-Term Investments	$8.100M	$8.100M	$51.60M
Other Short-Term Assets	$3.641M	$20.40M	$323.0K
YoY Change	1027.24%	-9.73%	-81.93%
Inventory	$3.454M	$3.500M	$3.170M
Prepaid Expenses	$11.26M		$13.26M
Receivables	$25.54M	$20.50M	$28.90M
Other Receivables	$8.400M	$8.400M	$2.500M
Total Short-Term Assets	$146.1M	$146.1M	$166.3M
YoY Change	-12.12%	-12.15%	-18.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.481M	$18.90M	$3.304M
YoY Change	-24.91%	-13.3%	-16.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.100M	$5.100M	$6.300M
YoY Change	-19.05%	-19.05%	-18.18%
Total Long-Term Assets	$98.08M	$98.10M	$68.61M
YoY Change	42.96%	43.0%	22.26%
TOTAL ASSETS
Total Short-Term Assets	$146.1M	$146.1M	$166.3M
Total Long-Term Assets	$98.08M	$98.10M	$68.61M
Total Assets	$244.2M	$244.2M	$234.9M
YoY Change	3.97%	3.96%	-9.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.08M	$12.10M	$19.18M
YoY Change	-37.05%	-36.98%	-7.26%
Accrued Expenses	$61.33M	$85.40M	$69.03M
YoY Change	-11.16%	19.11%	48.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$14.29M	$14.30M
YoY Change
Total Short-Term Liabilities	$114.3M	$114.3M	$90.84M
YoY Change	25.78%	25.88%	35.35%
LONG-TERM LIABILITIES
Long-Term Debt	$84.03M	$84.00M	$94.96M
YoY Change	-11.52%	-11.58%	-37.48%
Other Long-Term Liabilities	$51.90M	$51.90M	$31.60M
YoY Change	64.24%	64.24%	444.83%
Total Long-Term Liabilities	$84.03M	$135.9M	$94.96M
YoY Change	-11.52%	7.35%	-39.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$114.3M	$114.3M	$90.84M
Total Long-Term Liabilities	$84.03M	$135.9M	$94.96M
Total Liabilities	$250.2M	$250.2M	$217.4M
YoY Change	15.05%	15.09%	-3.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.338B		-$1.278B
YoY Change	4.7%		6.29%
Common Stock	$1.332B		$1.295B
YoY Change	2.83%		4.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.951M	-$6.000M	$17.46M
YoY Change
Total Liabilities & Shareholders Equity	$244.2M	$244.2M	$234.9M
YoY Change	3.97%	3.96%	-9.35%

Cashflow Statement

Concept	2020 Q4	2020	2019 Q4
OPERATING ACTIVITIES
Net Income	-$14.99M	-$60.00M	-$11.20M
YoY Change	33.89%	-20.64%	-63.51%
Depreciation, Depletion And Amortization	$2.940M	$900.0K	$1.900M
YoY Change	54.74%	0.0%	-9.52%
Cash From Operating Activities	-$5.640M	$773.0K	$1.570M
YoY Change	-459.24%	-96.55%	-77.7%
INVESTING ACTIVITIES
Capital Expenditures	-$10.03M	$46.00K	-$310.0K
YoY Change	3135.48%	-84.97%	416.67%
Acquisitions
YoY Change
Other Investing Activities	$10.85M	$43.45M	-$130.0K
YoY Change	-8446.15%	694.33%	-104.91%
Cash From Investing Activities	$820.0K	$33.40M	-$440.0K
YoY Change	-286.36%	546.97%	-116.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	20.00K	-$9.932M	0.000
YoY Change		-85.19%	-100.0%
NET CHANGE
Cash From Operating Activities	-5.640M	$773.0K	1.570M
Cash From Investing Activities	820.0K	$33.40M	-440.0K
Cash From Financing Activities	20.00K	-$9.932M	0.000
Net Change In Cash	-4.800M	$24.24M	1.130M
YoY Change	-524.78%	-161.33%	-97.18%
FREE CASH FLOW
Cash From Operating Activities	-$5.640M	$773.0K	$1.570M
Capital Expenditures	-$10.03M	$46.00K	-$310.0K
Free Cash Flow	$4.390M	$727.0K	$1.880M
YoY Change	133.51%	-96.71%	-73.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2020	us-gaap	Lessee Operating Lease Existence Of Option To Terminate LesseeOperatingLeaseExistenceOfOptionToTerminate	true
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y2M12D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2018	pbyi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y3M18D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M6D
CY2019	pbyi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P8Y7M6D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y2M12D
CY2020	pbyi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y2M12D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M6D
CY2020	pbyi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm	P9Y1M6D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y3M18D
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-59995000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-75595000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-113575000
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60037000
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	51607000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1000000
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28896000
CY2019Q4	us-gaap	Inventory Net InventoryNet	3170000
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	13259000
CY2020Q4	us-gaap	Deferred Rent Asset Net Current DeferredRentAssetNetCurrent	198000
CY2019Q4	us-gaap	Deferred Rent Asset Net Current DeferredRentAssetNetCurrent	154000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	8850000
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	8850000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3443000
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	323000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	146139000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	166296000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16404000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18522000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2481000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3304000
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	74140000
CY2019Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	40461000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3311000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4323000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1745000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1999000
CY2020Q4	us-gaap	Assets Assets	244220000
CY2019Q4	us-gaap	Assets Assets	234905000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12076000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	19183000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	61325000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	69030000
CY2020Q4	pbyi	Accrued In Licensed Rights Current AccruedInLicensedRightsCurrent	20993000
CY2020Q4	pbyi	Post Marketing Commitment Liability Current PostMarketingCommitmentLiabilityCurrent	2481000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3094000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2624000
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	14286000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	114255000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	90837000
CY2020Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	25963000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19549000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22643000
CY2020Q4	pbyi	Post Marketing Commitment Liability Noncurrent PostMarketingCommitmentLiabilityNoncurrent	6379000
CY2019Q4	pbyi	Post Marketing Commitment Liability Noncurrent PostMarketingCommitmentLiabilityNoncurrent	9000000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	84025000
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	94962000
CY2020Q4	us-gaap	Liabilities Liabilities	250171000
CY2019Q4	us-gaap	Liabilities Liabilities	217442000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40086387
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40086387
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39203304
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39203304
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1331676000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1295033000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	62000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1337631000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1277636000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-5951000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	17463000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	244220000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	234905000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	272260000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	250991000
CY2018	pbyi	Cost Of Sales CostOfSales	34621000
CY2020	us-gaap	Operating Expenses OperatingExpenses	255512000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-30402000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-39045000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	489000
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	2847000
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	1796000
CY2020	us-gaap	Interest Expense InterestExpense	14046000
CY2019	us-gaap	Interest Expense InterestExpense	15019000
CY2018	us-gaap	Interest Expense InterestExpense	10985000
CY2020	pbyi	Legal Verdict Expenses LegalVerdictExpenses	16196000
CY2019	pbyi	Legal Verdict Expenses LegalVerdictExpenses	16350000
CY2018	pbyi	Legal Verdict Expenses LegalVerdictExpenses	9000000
CY2019	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-8103000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	367000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	128000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-714000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-29386000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-36497000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18903000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-59788000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-75542000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-113558000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	207000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	53000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-59995000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-59995000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75595000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-113575000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.52
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.95
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.99
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39576107
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38768653
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37942411
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-65000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	72000
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-12000
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-3000
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-2000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60057000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-75521000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-113587000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	53302000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	86939000
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	7652000
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-12000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-113575000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	34306000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	57327000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1351000
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-2000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	36575000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	68000
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-3000
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-65000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-59995000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-5951000
CY2020	us-gaap	Profit Loss ProfitLoss	-59995000
CY2019	us-gaap	Profit Loss ProfitLoss	-75595000
CY2018	us-gaap	Profit Loss ProfitLoss	-113575000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10033000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	8077000
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7384000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	36575000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	57327000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	86939000
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1000000
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-54000
CY2019	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-1183000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8047000
CY2018	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	-289000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2353000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8123000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11103000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	284000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	545000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	596000
CY2020	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-2251000
CY2019	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-568000
CY2018	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	840000
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	3120000
CY2019	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1464000
CY2018	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1787000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7107000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1526000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7008000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	19251000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	22599000
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	15783000
CY2020	us-gaap	Increase Decrease In Deferred Leasing Fees IncreaseDecreaseInDeferredLeasingFees	44000
CY2019	us-gaap	Increase Decrease In Deferred Leasing Fees IncreaseDecreaseInDeferredLeasingFees	154000
CY2020	pbyi	Increase Decrease In Post Marketing Commitment Liability IncreaseDecreaseInPostMarketingCommitmentLiability	-140000
CY2019	pbyi	Increase Decrease In Post Marketing Commitment Liability IncreaseDecreaseInPostMarketingCommitmentLiability	9000000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	773000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	22376000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24105000
CY2020	pbyi	Payments To Acquire Property Plant And Equipment Excluding Capital Improvements PaymentsToAcquirePropertyPlantAndEquipmentExcludingCapitalImprovements	46000
CY2019	pbyi	Payments To Acquire Property Plant And Equipment Excluding Capital Improvements PaymentsToAcquirePropertyPlantAndEquipmentExcludingCapitalImprovements	306000
CY2018	pbyi	Payments To Acquire Property Plant And Equipment Excluding Capital Improvements PaymentsToAcquirePropertyPlantAndEquipmentExcludingCapitalImprovements	439000
CY2018	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	170000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	29826000
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	127198000
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	107502000
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	28135000
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	73275000
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	104532000
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	20000000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-57623000
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1351000
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	7652000
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	8444000
CY2019	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	25000000
CY2018	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	105000000
CY2020	us-gaap	Repayments Of Debt RepaymentsOfDebt	8444000
CY2019	us-gaap	Repayments Of Debt RepaymentsOfDebt	80000000
CY2019	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	7793000
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	5625000
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4201000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	68000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-67067000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	108451000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	24244000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-39528000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	26723000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	73210000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	112738000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	86015000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	97454000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	73210000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1745000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	13007000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	112738000
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	20000000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	25000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	9703000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	11739000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	8055000
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	207000
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	53000
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	17000
CY2020	pbyi	Number Of Subsidiaries NumberOfSubsidiaries	2
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-60000000.0
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	800000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85300000
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	8100000
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates: </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of revenues and expenses for the period presented. Accordingly, actual results could differ from those estimates. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant estimates include estimates for variable consideration for which reserves were established. These estimates are included in the calculation of net revenues and include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products.</p>
CY2020	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.
CY2020	us-gaap	Lessee Operating Lease Option To Terminate LesseeOperatingLeaseOptionToTerminate	Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.
CY2020Q4	pbyi	Incremental Costs Expenses IncrementalCostsExpenses	0
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3443000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	12200000
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	13200000
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	79813000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	79813000
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	92840000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	62000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	92902000
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents, marketable securities, and accounts receivable, net. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at December 31, 2020, were approximately $101.8 million. The Company does not believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-1/P-1 or better by Standard and Poor’s Rating Service and Moody’s Investors Service at the time of purchase. </p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells its products in the United States primarily through specialty pharmacies and specialty distributors. Therefore, wholesale distributors and large pharmacy chains account for a large portion of its accounts receivables, net and product revenues, net. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for credit loss primarily based on the credit worthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions. The Company recorded $1.0 million and $0 as an allowance for credit loss and the related credit loss expense in the years ended December 31, 2020 and 2019, respectively.</p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s success depends on its ability to successfully commercialize NERLYNX. The Company currently has a single product with limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, NERLYNX, and expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company relies exclusively on third parties to formulate and manufacture NERLYNX and its drug candidates. The commercialization of NERLYNX and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company has no experience in drug formulation or manufacturing and does not intend to establish its own manufacturing facilities. The Company lacks the resources and expertise to formulate or manufacture NERLYNX and other drug candidates. While the drug candidates were being developed by Pfizer, both the drug substance and drug product were manufactured by third-party contractors. The Company is using the same third-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of NERLYNX. If the Company is unable to continue its relationships with one or more of these third-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on one or more third-party contractors to manufacture the commercial supply of drugs.</span></p>
CY2020Q4	pbyi	Cash And Cash Equivalents And Restricted Cash In Excess Of Insured Limits CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits	101800000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1000000.0
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2020Q4	pbyi	Average Incremental Borrowing Rate AverageIncrementalBorrowingRate	0.109
CY2020	pbyi	Reduction In Carrying Value Of Right Of Use Assets ReductionInCarryingValueOfRightOfUseAssets	1200000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6300000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3900000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3900000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	8000000.0
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	8000000.0
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	8000000.0
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	8000000.0
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	8000000.0
CY2020Q4	pbyi	Finite Lived Intangible Assets Amortization Expense Year Six FiniteLivedIntangibleAssetsAmortizationExpenseYearSix	8000000.0
CY2020Q4	pbyi	Finite Lived Intangible Assets Amortization Expense Year Seven FiniteLivedIntangibleAssetsAmortizationExpenseYearSeven	8000000.0
CY2020Q4	pbyi	Finite Lived Intangible Assets Amortization Expense Year Eight FiniteLivedIntangibleAssetsAmortizationExpenseYearEight	8000000.0
CY2020Q4	pbyi	Finite Lived Intangible Assets Amortization Expense Year Nine FiniteLivedIntangibleAssetsAmortizationExpenseYearNine	8000000.0
CY2020Q4	pbyi	Finite Lived Intangible Assets Amortization Expense Year Ten FiniteLivedIntangibleAssetsAmortizationExpenseYearTen	2000000.0
CY2020Q4	pbyi	Trade Accounts Receivable Net Excluding License Revenue Receivable TradeAccountsReceivableNetExcludingLicenseRevenueReceivable	21515000
CY2019Q4	pbyi	Trade Accounts Receivable Net Excluding License Revenue Receivable TradeAccountsReceivableNetExcludingLicenseRevenueReceivable	26180000
CY2020Q4	pbyi	License Revenue Receivable LicenseRevenueReceivable	2500000
CY2019Q4	pbyi	License Revenue Receivable LicenseRevenueReceivable	2500000
CY2020Q4	pbyi	Royalty Revenue Receivable RoyaltyRevenueReceivable	2528000
CY2019Q4	pbyi	Royalty Revenue Receivable RoyaltyRevenueReceivable	216000
CY2020Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	26543000
CY2019Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	28896000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1000000
CY2020Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	25543000
CY2019Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	28896000
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1000000.0
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1000000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1000000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11262000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13259000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1999000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	15258000
CY2020Q4	pbyi	Deposit For Manufacturing Costs Current DepositForManufacturingCostsCurrent	3376000
CY2020Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	67000
CY2019Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	323000
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	323000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	8015000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	8015000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	8015000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	8015000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8632000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9163000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6151000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5859000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2481000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3304000
CY2020	us-gaap	Depreciation Depreciation	900000
CY2019	us-gaap	Depreciation Depreciation	900000
CY2018	us-gaap	Depreciation Depreciation	1100000
CY2020	pbyi	Fixed Lease Expense FixedLeaseExpense	4700000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	400000
CY2019	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4700000
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4700000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5365000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5483000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5631000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5805000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5983000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1509000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	29776000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7133000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	22643000
CY2020	us-gaap	Sublease Income SubleaseIncome	400000
CY2019	us-gaap	Sublease Income SubleaseIncome	200000
CY2018	us-gaap	Sublease Income SubleaseIncome	0
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	8015000
CY2020Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	467000
CY2020Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	481000
CY2020Q4	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	495000
CY2020Q4	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	510000
CY2020Q4	us-gaap	Lessor Operating Lease Payments To Be Received Five Years LessorOperatingLeasePaymentsToBeReceivedFiveYears	525000
CY2020Q4	us-gaap	Lessor Operating Lease Payments To Be Received Thereafter LessorOperatingLeasePaymentsToBeReceivedThereafter	133000
CY2020Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	2611000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	5569000
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.109
CY2020Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	90000000
CY2019Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	50000000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15860000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9539000
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	74140000
CY2019Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	40461000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	34065000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	74140000
CY2020Q4	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	22724000
CY2019Q4	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	31350000
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	8604000
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	8866000
CY2020Q4	pbyi	Accrued Development Costs AccruedDevelopmentCosts	3474000
CY2019Q4	pbyi	Accrued Development Costs AccruedDevelopmentCosts	8502000
CY2020Q4	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	9014000
CY2019Q4	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	7978000
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	7788000
CY2019Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1618000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4820000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4138000
CY2020Q4	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	1904000
CY2019Q4	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	2546000
CY2020Q4	pbyi	Accrued Professional Fees Liability Current AccruedProfessionalFeesLiabilityCurrent	1420000
CY2019Q4	pbyi	Accrued Professional Fees Liability Current AccruedProfessionalFeesLiabilityCurrent	1775000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	383000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	266000
CY2020Q4	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	752000
CY2019Q4	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	869000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	442000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1122000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	61325000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	69030000
CY2020Q4	pbyi	Accrued Legal Verdict Expense Non Current AccruedLegalVerdictExpenseNonCurrent	24822000
CY2020Q4	pbyi	Accrued Clinical Research Organization Services Noncurrent AccruedClinicalResearchOrganizationServicesNoncurrent	908000
CY2020Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	233000
CY2020Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	25963000
CY2020Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	87288000
CY2019Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	69030000
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	100000000
CY2020	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2024-06-01
CY2020Q4	pbyi	Accretion Of Final Interest Payment AccretionOfFinalInterestPayment	3313000
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	14286000
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	5002000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	84025000
CY2020Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	3666000
CY2020Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	8668000
CY2019Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	8668000
CY2019Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	1701000
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	5002000
CY2019Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	6967000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2000000.0
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1500000
CY2018	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	900000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	864881
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	790642
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	529443
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2021-10-04
CY2020	pbyi	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	36575000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6134513
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	87.91
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	220060000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	315566
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	59.13
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	183837
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	51.96
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	200743
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	35.88
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5063000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	356955
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	116.96
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5708544
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	87.49
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7762000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	340241
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	82.42
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1951000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	700853
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.40
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	128406
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	38.71
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	87625
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	15.42
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	995000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	790429
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	104.76
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5042325
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.03
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	18202
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.75
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	119000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	715634
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	90.51
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5009342
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	71.42
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3458000
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	899672
CY2020Q4	pbyi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice	11.18
CY2020Q4	pbyi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue	1106000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4109670
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	84.61
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2352000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.81
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.08
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	45.62
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	779292
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	33.75
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	340241
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.08
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	551933
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	33.56
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	128406
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	26.27
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	439194
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	19.38
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	700853
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.81
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	240375
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	25.57
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	899672
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	8.71
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1400000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1500000
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1900000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	124000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	53000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	17000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	83000
CY2020	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	207000
CY2019	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	53000
CY2018	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	17000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	207000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	53000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	13200000
CY2020	pbyi	Income Tax Benefit Due To Research And Development Tax Credits IncomeTaxBenefitDueToResearchAndDevelopmentTaxCredits	5200000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1300000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-12540000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-15830000
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-23771000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2304000
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2453000
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2791000
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	83000
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	13660000
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	21834000
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	10932000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	5231000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	14946000
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	5630000
CY2020	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-2116000
CY2019	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-2792000
CY2018	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	15750000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8655000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	14240000
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5527000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	207000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	53000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	261472000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	260555000
CY2020Q4	pbyi	Deferred Tax Assets Business Credit Carryforward DeferredTaxAssetsBusinessCreditCarryforward	55574000
CY2019Q4	pbyi	Deferred Tax Assets Business Credit Carryforward DeferredTaxAssetsBusinessCreditCarryforward	50343000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	58112000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	60967000
CY2020Q4	pbyi	Deferred Tax Assets Accrued Legal Verdict DeferredTaxAssetsAccruedLegalVerdict	11880000
CY2019Q4	pbyi	Deferred Tax Assets Accrued Legal Verdict DeferredTaxAssetsAccruedLegalVerdict	7624000
CY2020Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	3093000
CY2019Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	2839000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	561000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	9000
CY2020Q4	pbyi	Deferred Tax Asset Lease Liabilities DeferredTaxAssetLeaseLiabilities	5657000
CY2019Q4	pbyi	Deferred Tax Asset Lease Liabilities DeferredTaxAssetLeaseLiabilities	6145000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	804000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	13000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	397153000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	388495000
CY2020Q4	pbyi	Deferred Tax Liabilities Lease Right Of Use Asset DeferredTaxLiabilitiesLeaseRightOfUseAsset	4099000
CY2019Q4	pbyi	Deferred Tax Liabilities Lease Right Of Use Asset DeferredTaxLiabilitiesLeaseRightOfUseAsset	4505000
CY2020Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Inventory Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts	21000
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	464000
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	76000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4584000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4581000
CY2020Q4	pbyi	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	392569000
CY2019Q4	pbyi	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	383914000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	392569000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	383914000
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	8700000
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14200000
CY2020	pbyi	Operating Loss Carryforwards Expiration Dates Federal OperatingLossCarryforwardsExpirationDatesFederal	2033
CY2020	pbyi	Operating Loss Carryforwards Expiration Dates State OperatingLossCarryforwardsExpirationDatesState	2033
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1968000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8777000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7151000
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	8422000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1308000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1613000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1626000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3276000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1968000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8777000
CY2020Q4	pbyi	Milestone Payments Maximum Amount MilestonePaymentsMaximumAmount	187500000
	pbyi	Milestone Payment MilestonePayment	20600000
CY2020	pbyi	Percentage Of Unpaid Portion Of Milestone Payments Interest Rate PercentageOfUnpaidPortionOfMilestonePaymentsInterestRate	0.0625
CY2020Q4	us-gaap	Contractual Obligation ContractualObligation	67221000
CY2020Q4	pbyi	Potential Milestone Payments PotentialMilestonePayments	18400000
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	51217000
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	70582000
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50754000
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52557000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-16933000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	3395000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-31463000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-14994000
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16933000
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3395000
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-31463000
CY2020Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14994000
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39291162
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39432030
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39695444
CY2020Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39881131
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39291162
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39997571
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39695444
CY2020Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39881131
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	99067000
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53919000
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	56352000
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	62922000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-10087000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-37424000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-16885000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-11199000
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10087000
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37424000
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16885000
CY2019Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11199000
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.97
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38481824
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38647775
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38893757
CY2018Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	71079000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-24345000
CY2019Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39043706
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	66516000
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50767000
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	62629000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-44335000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-14201000
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-30694000
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24345000
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-44335000
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14201000
CY2018Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-30694000
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.65
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.17
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.80
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37699024
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37819767
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38043174
CY2018Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38201056

Files In Submission

Name	View Source	Status
0001564590-21-009840-index-headers.html	Edgar Link	pending
0001564590-21-009840-index.html	Edgar Link	pending
0001564590-21-009840.txt	Edgar Link	pending
0001564590-21-009840-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g5itxfhehtb4000001.jpg	Edgar Link	pending
g5itxfhehtb4000002.jpg	Edgar Link	pending
gumokbhwhuh3000001.jpg	Edgar Link	pending
gumokbhwhuh3000002.jpg	Edgar Link	pending
gumokbhwhuh3000003.jpg	Edgar Link	pending
gyqs5tvw5ygg000001.jpg	Edgar Link	pending
gyqs5tvw5ygg000002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbyi-10k_20201231.htm	Edgar Link	pending
pbyi-10k_20201231_htm.xml	Edgar Link	completed
pbyi-20201231.xsd	Edgar Link	pending
pbyi-20201231_cal.xml	Edgar Link	unprocessable
pbyi-20201231_def.xml	Edgar Link	unprocessable
pbyi-20201231_lab.xml	Edgar Link	unprocessable
pbyi-20201231_pre.xml	Edgar Link	unprocessable
pbyi-ex1019_197.htm	Edgar Link	pending
pbyi-ex101d_196.htm	Edgar Link	pending
pbyi-ex211_7.htm	Edgar Link	pending
pbyi-ex231_326.htm	Edgar Link	pending
pbyi-ex311_9.htm	Edgar Link	pending
pbyi-ex312_10.htm	Edgar Link	pending
pbyi-ex321_8.htm	Edgar Link	pending
pbyi-ex322_6.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2020 Q4 Form 10-K Financial Statement

#000156459021009840 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2020 Q4 Form 10-K Financial Statement

#000156459021009840 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi